April 8, 2009. The benefits are statistically significant in most, but not all the studies provided to the FDA. But, let’s be clear here: the patients on placebo are improving greatly in these studies – almost as much as those taking Seroquel.
Read More »On Medical Treatments & Products
NCHR Testimony on Fablyn
September 8, 2008. Osteoporosis is a serious disease. Fortunately, there are numerous treatments available, and those options should help the FDA determine whether the risks of this drug, Fablyn, outweigh the benefits.
Read More »NCHR Testimony at FDA on the NeuroStar TMS System for Major Depression
January 26, 2007. Depression is a serious and debilitating disease. The use of ineffective treatments can contribute to feelings of hopelessness, which in turn can worsen the symptoms and even result in suicide.
Read More »NCHR Statement on FDA ‘Approvable’ Letter for Breast Implant Manufacturer
September 24, 2005. The Food and Drug Administration (FDA) issued an “approvable letter” to Inamed Corporation for their silicone gel breast implants, and NCHR finds this unacceptable.
Read More »NCHR Statement on FDA Breast Implant Decision
July 28, 2005. The Food and Drug Administration (FDA) has issued an “approvable letter” to Mentor regarding their silicone gel breast implants. This does not mean that these implants have been approved, but it is a warning sign that corporate pressure on the FDA has once again put women’s health at risk.
Read More »